默沙东产品在华获批治疗不可切除的非转移性肝细胞癌

E公司
13 Jun

人民财讯6月13日电,6月13日,默沙东宣布其PD-1抑制剂帕博利珠单抗(商品名:可瑞达®)已获得中国国家药品监督管理局(NMPA)批准,和仑伐替尼联合经动脉化疗栓塞(TACE),用于治疗不可切除的非转移性肝细胞癌患者。此次新适应症的获批是基于III期临床试验LEAP-012研究的数据。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10